Syndax Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Syndax Pharmaceuticals, Inc. (SNDX) on June 10, 2026. The filing reports the closing of a private placement transaction involving the issuance of convertible debt securities.
Key Financial Metrics
- Debt Issuance: $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031.
- Net Proceeds: Approximately $243.0 million after deducting placement agent fees and expenses.
- Interest Rate: 2.25% per annum.
- Maturity Date: 2031.
- Conversion Terms: Initial conversion rate of 54.5256 shares of Common Stock per $1,000 principal amount of Notes.
- Maximum Dilution: Up to 13,631,400 shares of Common Stock may be issued upon conversion.
Material Changes
The primary material change is the creation of a new direct financial obligation and the unregistered sale of equity-linked securities. The Company has increased its debt load by $250.0 million and potential equity dilution by up to 13.6 million shares. No prior comparable period data is provided in this filing as it is a transaction-specific report.
Outlook, Management Commentary, and Risks
Use of Proceeds: Management intends to use the net proceeds for general corporate purposes, specifically working capital, research and development expenditures, commercialization activity, and business development.
Risks and Contingencies: The filing includes standard forward-looking statements regarding the anticipated use of proceeds. Actual results may differ due to market risks, trends, and conditions. The Notes and shares issuable upon conversion are not registered under the Securities Act and may not be offered or sold in the U.S. absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the specific terms of the Indenture and Notes attached as Exhibits 4.1 and 4.2.
- Confirm the impact of the 13,631,400 potential shares on current share count and earnings per share.
- Review the Company's cash burn rate to assess if the $243.0 million in net proceeds is sufficient for the stated R&D and commercialization goals.
- Check for any covenants in the Indenture that may restrict future financing or operational flexibility.